Skip to main content

B Share Class Portfolio

B Share Class Portfolio

Please click on the icons below to learn more about the portfolio of companies held by the B Ordinary Shares (SENECA GROWTH CAPITAL VCT PLC B ORD 1P).

Current Portfolio

+ Click for info

Abingdon Health

- Click to close

Abingdon Health


Abingdon Health (AIM: ABDX) is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world.

To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. The Company has developed and is manufacturing the AbC-19 Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The same IgG antibodies that are present following infection or vaccination.

+ Click for info

Arecor Ltd

- Click to close

Arecor Ltd


Arecor was a spin-out from Insense (qv) to commercialise technology developed by Insense for enabling biologics to maintain their integrity without the need for refrigeration – this both reduces cost and also helps deployment in developing countries where temperature monitored cold storage facilities are in short supply. The technology also assists in maintaining the integrity and function of proteins exposed to ionizing radiation as the means of sterilisation.

Visit the Arecor website here

+ Click for info

Bright Network

- Click to close

Bright Network


Bright Network is a media technology platform which enables blue-chip employers to reach, identify and recruit high-quality graduates and young professionals. London-based Bright Network is led by serial entrepreneur James Uffindell, who previously established, grew, and successfully exited from another business in the education sector. The business is chaired by Zach Miles, who was the founder and latterly CEO of Vedior, a multinational recruitment company, which was acquired by Randstad for €3.3 billion.

Its platform uses advanced data analytics and cutting-edge technology to pre-screen candidates and ensure that its membership contains only the top 20% of graduate talent. The quality of Bright Network’s membership helps drives efficiencies in the recruitment process and improved candidate shortlisting outcomes for employers. As a result, the business has established a strong client base of over 250 employers, which includes global blue-chip organisations such as Bloomberg, Deloitte, Goldman Sachs, Morgan Stanley, PwC, P&G SkyScanner and Vodafone.

+ Click for info

Evgen Pharma

- Click to close

Evgen Pharma


Evgen is based in Liverpool, at the Liverpool Science Park and was founded in 2007 by Dr Stephen Franklin.

Evgen is a clinical stage drug development company whose lead programmes are in cancer and subarachnoid haemorrhage (a type of stroke). It is also carrying out preclinical work in relapsing remitting multiple sclerosis.

Evgen’s core technology is Sulforadex®, a novel, synthetic and stabilised version of the naturally occurring compound sulforaphane. Sulforaphane is an established anti-cancer agent that benefits from a huge amount of peer-reviewed scientific literature identifying both its anti-cancer and neuroprotective characteristics. However, its commercial development as a potential prescription medicine has been prevented by the instability of the compound. Evgen’s Sulforadex® technology overcomes this problem by creating a stable version of sulforaphane, which can be delivered as a tablet or capsule.

The potential of Sulforadex® has allowed Evgen to attract a highly experienced commercial, scientific and advisory team. The company is led by Chief Executive Dr Stephen Franklin, who has a track record in the commercialisation of intellectual property, and Chairman Barry Clare, the former director of the Boots Company plc and head of its Boots Healthcare International business.

Read more about evgen pharma here

+ Click for info

Fabacus

- Click to close

Fabacus


Fabacus is an independent software company that has developed a complete product lifecycle solution: Xelacore, aimed at bringing transparency to supply chain networks, with an initial focus on resolving the interaction and information flow between global licensors and their licensees.

Currently, there is a fundamentally flawed data capture process between licensors and licensees; and a disconnection from the framework of retail standards that have underpinned and continue to enable the retail value chain. This has resulted in an inability to correctly address known shortcomings in respect to data management and hinder the needed digital transformation of licensors in the digitally evolving retail landscape.

Fabacus’s solution, Xelacore, is a modular, Software as a Service solution with an intuitive interface and proprietary data aggregation and management engine that allows all stakeholders to operate on a single unified and collaborative platform. It bridges the gaps in an inefficient process within the current retail ecosystem by creating authenticated, enriched universal records that unlock opportunities, reduce risk and drive performance for both licensors and licensees.

+ Click for info

Old St Labs

- Click to close

Old St Labs


Old St Labs is a provider of cloud based, supplier collaboration tools for large, blue chip customers, enabling them to manage key supplier relationships and strategic project work. The core product, Vizibl, seeks to make supplier collaboration much more straight forward, with key focus on compliance, savings / efficiency and driving growth across the business.

 Vizibl is the only SaaS workspace that supports collaborative supplier relationships, bringing all points of contact together in one place, providing visibility across the company and eliminating duplication of efforts. Vizibl’s real-time reporting speeds up decision making, drawing on and sharing the expertise of the community in the process. The offering taps into a growing trend in supplier collaboration, having moved on from the initial focus on compliance, to an increased emphasis on savings / efficiency, and recent developments highlighting the benefits in terms of wider growth strategy for large customers.

 Vizibl provides the infrastructure, governance and reporting capabilities to optimise present supplier performance and acts as a springboard for those collaborative supplier relationships. The product is CRM / ERP agnostic, working alongside all major software providers to ensure the collaboration software is insightful and informative.

+ Click for info

Optibiotix Health

- Click to close

Optibiotix Health


OptiBiotix (AIM:OPTI) is developing a range of technologies, which modulate the human microbiome to prevent and manage human disease. A global market of strategic interest to pharmaceutical, food, health and wellbeing companies, the human microbiome is forecast to become one of the world’s fastest growth areas.

OptiBiotix identifies and develops microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits.

With an established pipeline of microbiome modulators, the OptiBiotix team works in the prevention and management of chronic lifestyle diseases including obesity, hypercholesterolemia and lipid profiles, and diabetes.

+ Click for info

Polarean Imaging Plc

- Click to close

Polarean Imaging Plc


Polarean Imaging plc is a healthcare technology company which has developed a state of the art proprietary drug-device combination addressing a specific global unmet need in the field of healthcare. The company’s technology has been developed over a number of years and provides a visual representation of ventilation and gas exchange in the lungs. Xenon, when polarised in Polarean’s proprietary drug-device system, permits functional, regional and quantitative imaging of the lungs using MRI, without the risk of exposing patients to ionising radiation. The technology is being used in the field of respiratory disease – both in the understanding and treatment of it.

+ Click for info

Poolbeg Pharma Plc

- Click to close

Poolbeg Pharma Plc


Poolbeg Pharma is a clinical-stage pharmaceutical company focused on the development and commercialisation of therapies to treat and prevent infectious diseases. Headquartered in London, the business is a spin out from Open Orphan Plc and the management team has proven capabilities in identifying, acquiring and accelerating assets through development to commercialisation. It has adopted a capital-light model which enables it to develop multiple products faster and more cost effectively than the traditional biotech model, and the company aspires to become a “one-stop shop” for big pharma to find Phase II ready products for development and commercialisation.

The company’s lead asset is POLB 001, a drug with the potential to treat serious unmet needs in patients suffering from severe influenza.

+ Click for info

Qudini

- Click to close

Qudini


Founded in 2012, Qudini is a B2B software company that provides customer experience SaaS solutions to organisations in retail, hospitality, the public sector and healthcare.

Qudini provides a software solution for appointment bookings, queue management, event management and task management – enabling businesses to improve shop floor operations by managing staff activity, breaks and performance, and by assigning tasks at store or head office level.

Qudini is aiming to revolutionise digital queue and appointment management. It achieves this through deployment of its data-centric, cloud-based (Amazon Web Services), cross-platform service, which improves a business’ ability to manage the flow of customers awaiting service, using algorithms to provide accurate, live data, such as estimated wait times. Wait times are relayed to the customer typically via an SMS/text sent from the Qudini platform. Through integration with various software platforms and compatible with wide variety of hardware, Qudini enables detailed analytics focused on customer trends, and provides a unique insight into areas such as customer footfall, peak demand times, and wait times.

+ Click for info

SilkFred

- Click to close

SilkFred


Silkfred is an online marketplace for independent ladies’ fashion brands. The business was founded in 2011 with the aim of creating an efficient marketplace for emerging fashion designers to bring products to market and establish their brand in the sector. The business now works with c.600 independent brands, selling to over 500k customers.

Silkfred acts as a central marketing and sales platform
for these brands, charging commission in exchange for these services, and as a result the business itself takes minimal inventory / working capital risk on new brands, lines or products.

The business model revolves around a market leading and scalable customer service platform, and as such Silkfred are continually investing in core infrastructure and constantly seeking innovative methods to enhance the customer experience.

+ Click for info

SkinBioTherapeutics Plc

- Click to close

SkinBioTherapeutics Plc


SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Cath O’Neill and Professor Andrew McBain.

 SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.

 The aim of the Company is to develop its SkinBiotix® technology into commercially successful products supported by a strong scientific evidence base. SkinBioTherapeutics’ commercial strategy is to engage health and wellbeing and/or pharmaceutical companies in early dialogue to build up relationships and maintain communication on technical progress until one or more commercial deals can be secured.

+ Click for info

SolasCure

- Click to close

SolasCure


SolasCure aims to support healthcare professionals with wound care products that significantly improve the health and wellbeing of patients with chronic wounds. Chronic wounds impact over 40 million people worldwide, with care consuming around 10% of health care expenditure in many countries; while spending on advanced wound care products is over £5 billion each year.

These figures continue to grow as prevalence of obesity and diabetes increases. SolasCure’s first product, Aurase® is a hydrogel containing a safe, active, highly-specific enzyme, isolated and cloned from medical maggots. The medical use of Aurase® should lead to faster wound cleaning – promoting better patient outcomes and reduced healthcare costs. SolasCure was born in 2017 as a spin-off from BRAIN, a leading German biotech company, and is currently preparing a clinical study for Aurase to reach market authorisation

+ Click for info

Ten80 Group

- Click to close

Ten80 Group


The company is a SAP focussed on-demand outcome-based delivery solution.

Its aim is to connect every SAP customer with every SAP consultant globally, delivering outcome-based projects rather than time-driven costs through the contractor or freelancer marketplace.

The SAP global consultancy market is estimated to be worth in excess of £300bn.

Exited Portfolio

+ Click for info

Abingdon Health

- Click to close

Abingdon Health


Abingdon Health (AIM: ABDX) is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world.

To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. The Company has developed and is manufacturing the AbC-19 Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The same IgG antibodies that are present following infection or vaccination.

+ Click for info

ADC Biotechnology

- Click to close

ADC Biotechnology


ADC Biotechnology is developing new process technology to help drug developers meet conjugation process challenges in the testing and production of new antibody drug conjugate (ADC)-based anti cancer drugs. The technology signals faster, simpler and less costly development for an exciting new family of drugs.

With surging numbers of “second generation” drugs in development, tumour-selective ADCs are building a significant position in the oncology field – the fastest growing sector in healthcare.

ADC Bio’s technology aims to become a new paradigm in the way ADCs are developed and manufactured, increasing accessibility for patients by helping to contain ADC production complexity and cost. The patented Lock – Release technology results in fast, simple and robust conjugation processes, with the potential to eliminate several process steps whilst enhancing product quality.

ADC Bio brings knowledge, experience and technical differentiation to the rapid growth ADC sector and is an ideal partner for basic research, development, scale-up and commercialisation challenges.

Read more about ADC Biotechnology here

+ Click for info

genedrive plc

- Click to close

genedrive plc


genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications.

genedrive is based in Manchester, United Kingdom. The business was floated on the London AIM market in 2007, trading as Epistem Holdings Inc but was renamed genedrive plc in July 2016 to reflect the new direction of the company targeting molecular diagnostic requirements at the point of need. The legacy contract research services divisions were divested in June 2018.
Read more about genedrive here

+ Click for info

Optibiotix Health

- Click to close

Optibiotix Health


OptiBiotix (AIM:OPTI) is developing a range of technologies, which modulate the human microbiome to prevent and manage human disease. A global market of strategic interest to pharmaceutical, food, health and wellbeing companies, the human microbiome is forecast to become one of the world’s fastest growth areas.

OptiBiotix identifies and develops microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits.

With an established pipeline of microbiome modulators, the OptiBiotix team works in the prevention and management of chronic lifestyle diseases including obesity, hypercholesterolemia and lipid profiles, and diabetes.

+ Click for info

SkinBioTherapeutics Plc

- Click to close

SkinBioTherapeutics Plc


SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Cath O’Neill and Professor Andrew McBain.

 SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas.

 The aim of the Company is to develop its SkinBiotix® technology into commercially successful products supported by a strong scientific evidence base. SkinBioTherapeutics’ commercial strategy is to engage health and wellbeing and/or pharmaceutical companies in early dialogue to build up relationships and maintain communication on technical progress until one or more commercial deals can be secured.